Dr. Tang has over 12 years of drug discovery and development experiences. In 2012, as the President and CEO, he led Welichem Biotech Inc. into a successful acquisition agreement for it’s lead immunology drug candidate with GlaxoSmithKline (GSK). Liren received his PhD in Cell and Developmental Biology at the University of British Columbia.

Dr. Lyle has over 12 years of experiences in new drug discovery and development. He played an integral role in the development of WBI1001 and these efforts ultimately culminated in the $230M acquisition of WBI1001 by GSK in July 2012. Dr. Lyle holds a PhD in Chemistry from Simon Fraser University (SFU) and has authored numerous peer-reviewed scientific publications and patents.

Dr. Zhou is a Professor in the University of British Columbia and also on active staff at the BC Cancer Agency. He is a distinguished clinician, scientist and leading visionary in Immunology and Oncology in Canada and internationally. Dr. Zhou has lead and guided numerous clinical studies at various stages of clinical development. He received his PhD from the State University of New York and his MD from University of Toronto.